Captor Therapeutics (WAR:CTX) Ending Cash Position: zł2.35 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:CTX Captor Therapeutics SA WAR:CTX
36 GF Score
Price zł73.00
GF Value zł9.90
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Captor Therapeutics Ending Cash Position?

Captor Therapeutics WAR:CTX -0.27% 36 Ending Cash Position is zł2.35 Mil as of Mar. 2026. GuruFocus rates WAR:CTX with a GF Score™ of 36/100 and a GF Value™ of zł9.90 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Captor Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was zł2.35 Mil.

Captor Therapeutics's quarterly Ending Cash Position increased from Sep. 2025 (zł3.93 Mil) to Dec. 2025 (zł10.72 Mil) but then declined from Dec. 2025 (zł10.72 Mil) to Mar. 2026 (zł2.35 Mil).

Captor Therapeutics's annual Ending Cash Position declined from Dec. 2023 (zł75.70 Mil) to Dec. 2024 (zł39.26 Mil) and declined from Dec. 2024 (zł39.26 Mil) to Dec. 2025 (zł10.72 Mil).

Captor Therapeutics Ending Cash Position Related Terms

Captor Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Captor Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Captor Therapeutics Ending Cash Position Chart

Captor Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only 117.94 71.04 75.70 39.26 10.72

Captor Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.62 15.20 3.93 10.72 2.35
WAR:CTX
36GF Score
Captor Therapeutics SA WAR:CTX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Captor Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Captor Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=39.257+-28.538
=10.72

Captor Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=10.719+-8.371
=2.35

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of zł2.35 Mil mean?
Captor Therapeutics (WAR:CTX) has a Ending Cash Position of zł2.35 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Captor Therapeutics and its competitors.
Is Captor Therapeutics' Ending Cash Position too high?
Captor Therapeutics' current Ending Cash Position is zł2.35 Mil. Overall, Captor Therapeutics has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Captor Therapeutics' Ending Cash Position compare to VRTX and REGN?
Captor Therapeutics' Ending Cash Position of zł2.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Captor Therapeutics and its competitors. Captor Therapeutics's current Ending Cash Position is zł2.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Captor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Captor Therapeutics (WAR:CTX) is currently considered Significantly Overvalued. The stock's GF Value™ is zł9.90, compared to a current price of zł73.00 — trading 637.4% above its estimated fair value. The current Ending Cash Position is zł2.35 Mil. Captor Therapeutics' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Captor Therapeutics (WAR:CTX), the current Ending Cash Position is zł2.35 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Captor Therapeutics (WAR:CTX) Overvalued in 2026?

Based on GuruFocus' analysis, Captor Therapeutics stock appears to be overvalued. The current stock price of zł73.00 is trading 637.4% above its estimated GF Value™ of zł9.90. GuruFocus considers Captor Therapeutics to be Significantly Overvalued.

Key valuation signals for WAR:CTX:

  • Ending Cash Position: zł2.35 Mil
  • GF Value™: zł9.90 vs. price of zł73.00 (637.4% above fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the WAR:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Captor Therapeutics Business Description

Other Exchanges 60Q:Germany
Address ul. Dunska 11, Wroclaw, POL, 54-427
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
36GF Score

Get the complete analysis for WAR:CTX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł73.00
Price
zł9.90
GF Value